BACKGROUND: To evaluate the activity and safety of bevacizumab when given with standard 5FU/leukovorin (LV) regimens in patients with metastatic colorectal cancer who have failed irinotecan and oxaliplatin-based treatments. METHODS: Bevacizumab was given at 5 mg/kg as an IV infusion every 2 weeks. Patients received 5FU according to Roswell Park or the de Gramont regimen. RESULTS: Nineteen patients enrolled, median age 60, median PS: 1. Most common toxicity attributable to bevacizumab was mild hypertension, epistaxis and mild proteinuria; 1 patient had a CNS haemorrhage. The median number of cycles was 1 (8 weeks). Clinical benefit as disease stabilisation lasting 2-6 months was noted in 9 patients, whereas 10 progressed (median f/u: 5 months). TTP was 16 weeks, and the overall survival has not been reached (24+ weeks). CONCLUSIONS: Bevacizumab may result in growth arrest and clinical benefit in a substantial proportion of patients with colorectal cancer and no alternative treatment.
BACKGROUND: To evaluate the activity and safety of bevacizumab when given with standard 5FU/leukovorin (LV) regimens in patients with metastatic colorectal cancer who have failed irinotecan and oxaliplatin-based treatments. METHODS:Bevacizumab was given at 5 mg/kg as an IV infusion every 2 weeks. Patients received 5FU according to Roswell Park or the de Gramont regimen. RESULTS: Nineteen patients enrolled, median age 60, median PS: 1. Most common toxicity attributable to bevacizumab was mild hypertension, epistaxis and mild proteinuria; 1 patient had a CNS haemorrhage. The median number of cycles was 1 (8 weeks). Clinical benefit as disease stabilisation lasting 2-6 months was noted in 9 patients, whereas 10 progressed (median f/u: 5 months). TTP was 16 weeks, and the overall survival has not been reached (24+ weeks). CONCLUSIONS:Bevacizumab may result in growth arrest and clinical benefit in a substantial proportion of patients with colorectal cancer and no alternative treatment.
Authors: Lee Chun Park; Ho Sup Lee; Seong Hoon Shin; Seun Ja Park; Moo In Park; Sung Yong Oh; Hyuk Chan Kwon; Jin Ho Baek; Young Jin Choi; Myoung Joo Kang; Yang Soo Kim Journal: World J Gastroenterol Date: 2012-03-14 Impact factor: 5.742
Authors: A Abajo; J Rodriguez; N Bitarte; R Zarate; V Boni; M Ponz; A Chopitea; E Bandres; J Garcia-Foncillas Journal: Br J Cancer Date: 2010-10-12 Impact factor: 7.640
Authors: Libo Zhang; Kristen M Smith; Amy L Chong; Diana Stempak; Herman Yeger; Paula Marrano; Paul S Thorner; Meredith S Irwin; David R Kaplan; Sylvain Baruchel Journal: Neoplasia Date: 2009-05 Impact factor: 5.715
Authors: A Abajo; V Boni; I Lopez; M Gonzalez-Huarriz; N Bitarte; J Rodriguez; R Zarate; E Bandres; J Garcia-Foncillas Journal: Br J Cancer Date: 2012-06-14 Impact factor: 7.640